<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01666691</url>
  </required_header>
  <id_info>
    <org_study_id>ZAF-201</org_study_id>
    <nct_id>NCT01666691</nct_id>
  </id_info>
  <brief_title>An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects</brief_title>
  <official_title>Randomized, Double-Blind, Placebo Controlled, Dose Ranging Phase 2 Trial of Beloranib (ZGN-440 for Injectable Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects to Evaluate Weight Reduction, Safety, and Pharmacokinetics Over 12 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zafgen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zafgen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for
      certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly
      subcutaneous injections for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is designed to test the safety and efficacy of a drug called beloranib (ZGN-440
      for injectable suspension). It is to be tested for its ability to reduce weight in obese
      subjects. The study will provide information on how much ZGN-440 gets into the blood, how
      long it stays in the body, and how it affects other biological markers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of beloranib (ZGN-440 for injectable suspension) administered subcutaneously for 12 weeks</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Safety and tolerability of beloranib will be assessed by comparing frequency and severity of adverse events as well as changes in physical examinations, ECGs, vital signs and laboratory evaluations. Other safety oriented questionnaires and parameters (e.g. sleep quality, hemodynamic parameters) will be measured and evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight loss and responses in metabolic biomarkers over a dose range of ZGN-440</measure>
    <time_frame>Up to 13 weeks</time_frame>
    <description>Change from baseline in body weight and body composition (bioimpedance assessments), and scores of hunger/appetite over the dosing period will be evaluated to document beloranib's effect on obesity. Biomarkers of lipid metabolism will be measured to assess possible mechanisms of loss of body fat, as well as endocrinologic or anti-inflammatory markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics over a dose range of beloranib</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The plasma PK of beloranib and selected metabolites may be assessed following dose administration to compare systemic exposure and PK parameters over the range of doses. PK parameters include Cmax, Tmax, AUC24hour, AUC∞, volume of distribution, total clearance, terminal elimination constant, and half-life. Mean residence time may also be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the plasma pharmacokinetic profile of beloranib administered subcutaneously with the profiles obtained previously using an alternative formulation administered subcutaneously and with ZGN-433 (beloranib hemioxalate) administered intravenously</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent bioavailability over a dose range of beloranib</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Bioavailability will be estimated from the SC PK parameters compared to the profile from comparable doses in earlier IV administration studies.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ZGN-440 sterile diluent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg Beloranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg ZGN-440 for injectable suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.6 mg Beloranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.6 mg ZGN-440 for injectable suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.2 mg Beloranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2 mg ZGN-440 for injectable suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.4 mg Beloranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.4 mg ZGN-440 for injectable suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.2 mg Beloranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.2 mg ZGN-440 for injectable suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beloranib</intervention_name>
    <description>Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.</description>
    <arm_group_label>0.3 mg Beloranib</arm_group_label>
    <arm_group_label>0.6 mg Beloranib</arm_group_label>
    <arm_group_label>1.2 mg Beloranib</arm_group_label>
    <arm_group_label>2.4 mg Beloranib</arm_group_label>
    <arm_group_label>3.2 mg Beloranib</arm_group_label>
    <other_name>ZGN-440 for injectable suspension</other_name>
    <other_name>ZGN-440</other_name>
    <other_name>ZGN-433</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>ZGN-440 sterile diluent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese volunteers weighing ≥ 50 kg

          -  BMI ≥ 30 and ≤ 50 kg/m2

          -  Stable body weight during the past 2 months

          -  Type 2 diabetes mellitus is allowed

        Exclusion Criteria:

          -  Use of weight loss agents in the past month

          -  Current, clinically significant eating disorder

          -  Type 1 diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J K Marjason, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Q-Pharm Clinics, Royal Brisbane and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q-Pharm Clinics, Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2012</study_first_submitted>
  <study_first_submitted_qc>August 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2012</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obese</keyword>
  <keyword>Obesity</keyword>
  <keyword>Overweight</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Weight reduction</keyword>
  <keyword>Beloranib</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

